WEKO3
アイテム
An attenuated vaccinia vaccine encoding the severe acute respiratory syndrome coronavirus-2 spike protein elicits broad and durable immune responses, and protects cynomolgus macaques and human angiotensin-converting enzyme 2 transgenic mice from severe acute respiratory syndrome coronavirus-2 and its variants
http://hdl.handle.net/10422/00013482
http://hdl.handle.net/10422/00013482a670a1de-37d9-4256-a6b3-e8694322e93f
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
fmicb.2022.967019 (3.0 MB)
|
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original
author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| Item type | 学術雑誌論文 / Journal Article(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2023-01-12 | |||||
| タイトル | ||||||
| タイトル | An attenuated vaccinia vaccine encoding the severe acute respiratory syndrome coronavirus-2 spike protein elicits broad and durable immune responses, and protects cynomolgus macaques and human angiotensin-converting enzyme 2 transgenic mice from severe acute respiratory syndrome coronavirus-2 and its variants | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | SARS-CoV-2 | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | DIs-based SARS-CoV-2 vaccine | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | animal model | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | SARS-CoV-2 variants | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | broad immune response | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | durable immune response | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | quantitative proteomics | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | journal article | |||||
| 著者 |
ISHIGAKI, Hirohito
× ISHIGAKI, Hirohito× YASUI, Fumihiko× NAKAYAMA, Misako× ENDO, Akinori× YAMAMOTO, Naoki× YAMAJI, Kenzaburo× NGUYEN, Cong Thanh× KITAGAWA, Yoshinori× SANADA, Takahiro× HONDA, Tomoko× MUNAKATA, Tsubasa× HIGA, Masahiko× TOYAMA, Sakiko× KONO, Risa× TAKAGI, Asako× MATSUMOTO, Yusuke× KOSEKI, Aya× HAYASHI, Kaori× SHIOHARA, Masanori× ISHII, Koji× SAEKI, Yasushi× ITOH, Yasushi× KOHARA, Michinori |
|||||
| 著者別名 |
石垣, 宏仁
× 石垣, 宏仁× 仲山, 美沙子× 北川, 善紀× 林, 香里× 塩原, 正規× 伊藤, 靖 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | As long as the coronavirus disease-2019 (COVID-19) pandemic continues, new variants of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) with altered antigenicity will emerge. The development of vaccines that elicit robust, broad, and durable protection against SARS-CoV-2 variants is urgently required. We have developed a vaccine consisting of the attenuated vaccinia virus Dairen-I (DIs) strain platform carrying the SARS-CoV-2 S gene (rDIs-S). rDIs-S induced neutralizing antibody and T-lymphocyte responses in cynomolgus macaques and human angiotensin-converting enzyme 2 (hACE2) transgenic mice, and the mouse model showed broad protection against SARS-CoV-2 isolates ranging from the early-pandemic strain (WK-521) to the recent Omicron BA.1 variant (TY38-873). Using a tandem mass tag (TMT)-based quantitative proteomic analysis of lung homogenates from hACE2 transgenic mice, we found that, among mice subjected to challenge infection with WK-521, vaccination with rDIs-S prevented protein expression related to the severe pathogenic effects of SARS-CoV-2 infection (tissue destruction, inflammation, coagulation, fibrosis, and angiogenesis) and restored protein expression related to immune responses (antigen presentation and cellular response to stress). Furthermore, long-term studies in mice showed that vaccination with rDIs-S maintains S protein-specific antibody titers for at least 6 months after a first vaccination. Thus, rDIs-S appears to provide broad and durable protective immunity against SARS-CoV-2, including current variants such as Omicron BA.1 and possibly future variants. | |||||
| 書誌情報 |
en : Frontiers in Microbiology 発行日 2022-11-18 |
|||||
| 出版者 | ||||||
| 出版者 | Frontiers Media S.A. | |||||
| ISSN | ||||||
| 収録物識別子タイプ | ISSN | |||||
| 収録物識別子 | 1664-302X | |||||
| PMID | ||||||
| 関連タイプ | isIdenticalTo | |||||
| 識別子タイプ | PMID | |||||
| 関連識別子 | 36466631 | |||||
| PMCID | ||||||
| 識別子タイプ | URI | |||||
| 関連識別子 | http://www.ncbi.nlm.nih.gov/pmc/articles/pmc9716133/ | |||||
| 関連名称 | PMC9716133 | |||||
| DOI | ||||||
| 関連タイプ | isIdenticalTo | |||||
| 識別子タイプ | DOI | |||||
| 関連識別子 | https://doi.org/10.3389/fmicb.2022.967019 | |||||
| 関連名称 | 10.3389/fmicb.2022.967019 | |||||
| 権利 | ||||||
| 権利情報 | © 2022 Ishigaki, Yasui, Nakayama, Endo, Yamamoto, Yamaji, Nguyen, Kitagawa, Sanada, Honda, Munakata, Higa, Toyama, Kono, Takagi, Matsumoto, Koseki, Hayashi, Shiohara, Ishii, Saeki, Itoh and Kohara. | |||||
| フォーマット | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | application/pdf | |||||
| 著者版フラグ | ||||||
| 出版タイプ | VoR | |||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
| 資源タイプ | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | Journal Article | |||||
